The initiative, called the Vaccine Transition Option, gives trial participants ages 16 years and older who received a placebo the option to receive Pfizer’s COVID-19 vaccine while remaining in the study.
Participants in the placebo arm who want to receive the vaccine will be scheduled for an in-person visit, during which the study physician will provide and explain a new informed consent document.
The drugmaker hopes to administer first doses to all participants in the placebo arm who opt to get the vaccine by March 1.
More articles on pharmacy:
Moderna increases expected number of vaccine doses for 2021 by 20%
List prices for 589 drugs increase in the 1st days of 2021
US might administer half doses of Moderna’s COVID-19 vaccine to accelerate rollout
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.